2.1500 +0.01 (0.47%)
After hours: 7:53PM EDT
|Bid||2.1500 x 2200|
|Ask||2.1500 x 3200|
|Day's Range||1.8850 - 2.2700|
|52 Week Range||1.2800 - 7.7700|
|Beta (3Y Monthly)||1.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
The big shareholder groups in NewLink Genetics Corporation (NASDAQ:NLNK) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders ownRead More...
AMES, Iowa, Feb. 27, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that a late-breaking abstract reporting results from a Phase 2 study of NLG207, a.
AMES, Iowa, Feb. 27, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the fourth quarter and year ended 2018, as well as.
NewLink Genetics Corporation (NLNK) today announced that it will release its fourth quarter and full year 2018 financial results on Wednesday, February 27, 2019. NewLink Genetics' senior management team will host the conference call, which will be open to all listeners. The conference call will be webcast live and a link can be accessed through the NewLink Genetics website at https://edge.media-server.com/m6/p/dqg32drc.
NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Dr. Link’s presentation, “IDO Changes the T-cell Balance in the Tumor Microenvironment,” will occur on Wednesday, February 6th, at 9:15 AM ET, and will include a discussion of immune regulation in the tumor microenvironment and how indoximod’s mechanism of action lends itself to counter multiple elements of immune regulation. NewLink Genetics is a clinical stage biopharmaceutical company focused on developing novel immuno-oncology product candidates to improve the lives of patients with cancer.
If you're interested in NewLink Genetics Corporation (NASDAQ:NLNK), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
AMES, Iowa & SAN DIEGO-- -- Updated Phase 1 data for indoximod plus standard-of-care chemotherapy in newly diagnosed AML show post-induction minimal residual disease negativity rate of 86% and post-consolidation MRD negativity of 100% Safety data from this study indicate the combination treatment regimen was well tolerated with no regimen limiting toxicities observed NewLink Genetics Corporation announced ...
Charles Link has been the CEO of NewLink Genetics Corporation (NASDAQ:NLNK) since 2003. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then Read More...
NewLink Genetics Corporation (NLNK) reported today that Merck has begun the submission of a rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for V920 (rVSV∆G-ZEBOV-GP, live attenuated). This rolling submission is made pursuant to the FDA’s Breakthrough Therapy Designation for V920, which was announced by Merck in July 2016 and is anticipated to be completed in 2019.
AMES, Iowa, Nov. 06, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that the following abstracts have been published and are now available on the Society.
Investors need to pay close attention to NewLink Genetics (NLNK) stock based on the movements in the options market lately.
AMES, Iowa, Nov. 02, 2018 -- In a release issued under the same headline yesterday by NewLink Genetics Corporation (NASDAQ:NLNK), the balance statement included in the press.
NewLink (NLNK) delivered earnings and revenue surprises of 52.38% and -94.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Ames, Iowa-based company said it had a loss of 20 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss ...
AMES, Iowa, Nov. 01, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the third quarter 2018 and reviewed recent highlights.
NewLink Genetics Corporation (NLNK) announced today that an abstract with data pertaining to the use of the Company's investigational immuno-oncology molecule, indoximod, in combination therapy for patients with newly diagnosed acute myeloid leukemia (AML) has been accepted for an oral presentation at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition to be held at the San Diego Convention Center, San Diego, CA, December 1-4th, 2018. “We are pleased to have an abstract accepted for oral presentation at this year’s ASH Annual Meeting,” said Charles J. Link, Jr, MD, Chairman and Chief Executive Officer.
NewLink Genetics Corporation (NLNK), a clinical stage biopharmaceutical company focused on developing novel immuno-oncology therapeutic candidates, announced today it will present at the Stifel 2018 Healthcare Conference. The conference is being held on November 13 – 14 at the Lotte New York Palace Hotel in New York City, New York. NewLink Genetics is a clinical stage biopharmaceutical company focused on developing novel immuno-oncology product candidates to improve the lives of patients with cancer.
NewLink (NLNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.